ABSI
Absci CorporationNASDAQHealthcare$3.06-2.86%ClosedMarket Cap: $468.2M
As of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
2.43
P/S
167.23
EV/EBITDA
-4.01
DCF Value
$0.04
FCF Yield
-20.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
-1316.1%
Operating Margin
-4479.2%
Net Margin
-4113.7%
ROE
-59.7%
ROA
-65.9%
ROIC
-63.9%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $650.0K | $-29.6M | $-0.20 |
| FY 2025 | $2.8M | $-115.2M | $-0.84 |
| Q3 2025 | $378.0K | $-28.7M | $-0.20 |
| Q2 2025 | $593.0K | $-30.6M | $-0.24 |
Analyst Ratings
View AllNeedhamBuy
2026-03-30HC Wainwright & Co.Buy
2025-12-18NeedhamBuy
2025-12-12Morgan StanleyOverweight
2025-08-18NeedhamBuy
2025-08-13Trading Activity
Insider Trades
View AllBusch Andreasofficer: Chief Innovation Officer
BuyMon Mar 16
Pangalos Menelas Ndirector
SellThu Mar 05
Pangalos Menelas Ndirector
SellThu Mar 05
Walker Shelby J.officer: Chief Legal Officer
SellWed Mar 04
Walker Shelby J.officer: Chief Legal Officer
SellWed Mar 04
Company Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
2.01
Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.